President’s Message

Dear Colleague:

**Personalized medicine is redefining possible.** The U.S. Food and Drug Administration (FDA) is approving targeted therapies at a record pace, and the first FDA-approved gene transplants may allow us to eliminate disease in some patients by introducing re-arranged genes into human cells. At the same time, newly conceived testing paradigms and transformative artificial intelligence platforms anticipate an era in which we can predict, prevent, and treat disease in previously unimaginable ways.

But these developments challenge policymakers and health systems, most of which were designed to deliver one-size-fits-all medicine.

By exploring these challenges and proposing solutions for them, the 14th Annual Personalized Medicine Conference: Preparing for the New Possible will outline a path forward. Focusing on the present while considering the future, the conference convenes the world’s leading researchers, investors, industry executives, policy experts, payers, clinicians, and patient advocates to define the landscape and outlook for personalized medicine in science, business, and policy. We will examine the infrastructure and business strategies necessary to overcome scientific obstacles, optimize public policies, and change embedded medical norms as we seek to accelerate investment in and adoption of personalized medicine.

Thank you for being with us.

Sincerely yours,

Edward Abrahams, Ph.D.
President
Personalized Medicine Coalition
Thank You to Our Supporters

DIAMOND

Intermountain Precision Genomics

GOLD

AstraZeneca
Quest Diagnostics

SILVER

AMGEN
Bristol-Myers Squibb
Genentech
SomaLogic

BRONZE

2bPrecise
Foundation Medicine
Genomic Health
LabCorp
nanoString
Novartis
Thermo Fisher Scientific

BENEFICTOR

Bio
CareDx
endo
Janssen
LEK

FRIEND

AAGRX Ambrx Genetics
Amgen Lung Cancer Foundation
BUSINESS FINLAND
flatiron
FOLEY POLCY & LAWNER LLP

GNS HEALTHCARE
GREYBIRD VENTURES
Harvard Pilgrim HealthCare
Lilly
M2GEN
Moffitt Cancer Center

Pfizer
Catholic Health Initiatives
Dignity Health
Regeneron
SLOANE PARTNERS
Third Rock Ventures

MEDIA PARTNERS

genomeweb
greenough
Precision Medicine Journal
MassBio
STAT
We need to make the transition to a predict, prevent and protect health system.”

— Joshua Ofman, M.D., M.S.H.S., Senior Vice President, Global Value, Access and Policy, Amgen
7:00 am  Registration and Breakfast

8:00 am  Opening Remarks

  SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

8:10 am  Setting the Stage: Exploring the Promise of Personalized Medicine

  KEYNOTE | Elizabeth Nabel, M.D., President, Brigham Health

8:55 am  Shifting Systems: Identifying the Common Challenges and Notable Achievements of Government Efforts to Advance Personalized Medicine

Government executives have an enormous influence over the direction of health systems and can therefore play a role in developing personalized medicine — but they need to know what works and what doesn’t if their respective efforts to promote personalized medicine are going to succeed. With that in mind, government representatives from around the globe will discuss the competitive advantages various countries have in personalized medicine and explore the common challenges and notable achievements of government initiatives to advance the field during this panel discussion.

  MODERATOR | Antonio L. Andreu, M.D., Ph.D., Scientific Director, EATRIS European Infrastructure for Translational Medicine

  Ora Dar, Ph.D., Senior Expert, National Research & Development Projects, Technological Infrastructure Division, Israel Innovation Authority

  Tom Fowler, Ph.D., Deputy Chief Scientist, Director of Public Health, Genomics England

  Marc LePage, President, CEO, Genome Canada

  Liisa-Maria Voipio-Pulkki, M.D., Ph.D., Director General, Chief Medical Officer, Ministry of Social Affairs and Health, Finland

10:10 am  Networking Break

10:40 am  Evaluating Patients’ Priorities: Understanding Perspectives on Personalized Medicine — A Fireside Chat

  MODERATOR | Susan McClure, Founder, Publisher, Genome magazine; Board member, Personalized Medicine Coalition

  Emily Kramer-Golinkoff, Co-Founder, Emily’s Entourage; cystic fibrosis patient

  Bryce Olson, Global Marketing Director, Health and Life Sciences Group, Intel Corporation; prostate cancer patient

11:10 am  Automating Actionable: How Artificial Intelligence May Chart a Course for Personalized Medicine

Artificial intelligence may help inform personalized medicine in the future by perceiving which genes, proteins and other biological characteristics contribute to human disease. During this session, a diverse panel will discuss how artificial intelligence may accelerate drug development, improve clinical decision support and drive patient outcomes — and what that might mean for the future of health care.

  MODERATOR | William S. Dalton, Ph.D., M.D., Founder, Executive Chairman, M2Gen; Board member, Personalized Medicine Coalition

  Colin Hill, Chairman, CEO, Co-Founder, GNS Healthcare

  Tom Miller, Managing Partner, GreyBird Ventures LLC

  Gregg Talbert, Ph.D., Global Head of Digital and Personalized Health Care Partnering, Roche

  Darrell M. West, Ph.D., Vice President of Governance Studies, Director of the Center for Technology Innovation, Douglas Dillon Chair in Governance Studies, The Brookings Institution
12:25 pm  Seated Luncheon

1:40 pm  The Lay of the Lab: Exploring the State of the Clinical Laboratory Industry

**KEYNOTE | David P. King, J.D., Chairman, CEO, LabCorp**

2:25 pm  The Diagnostics Discussion: Evaluating the Extent to Which the Regulatory and Reimbursement Environment for Diagnostic Tests May Help or Hinder Personalized Medicine

The U.S. Food and Drug Administration and the U.S. Centers for Medicare and Medicaid Services have been working for over a decade to develop regulatory and reimbursement pathways that promote the development of innovative diagnostic tests. Many observers, however, believe the current regulatory and reimbursement landscape still limits the field. This panel of business leaders will discuss the extent to which the existing frameworks and proposed policies may help or hinder personalized medicine.

**MODERATOR | Joseph V. Ferrara, CEO, Boston Healthcare Associates**

**Michael Doherty**, Senior Vice President, Head of Product Development, Head of Research & Development, Foundation Medicine

**Julie Khani**, President, American Clinical Laboratory Association

**Kimberly Popovits**, Chairman of the Board, CEO, President, Genomic Health; Board member, Personalized Medicine Coalition

**Mark P. Stevenson**, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific

3:25 pm  Networking Break

3:55 pm  Examining Policies: Exploring How Emerging US Regulatory Approaches May Help Facilitate Personalized Care Regimens

The U.S. Food and Drug Administration (FDA) remains firmly committed to regulatory strategies designed to advance personalized medicine. During this wide-ranging fireside chat, two senior leaders from government and industry will discuss the agency’s latest actions impacting the oversight of personalized medicine products and services. The discussion will cover topics including but not limited to next-generation sequencing, diagnostic test regulation, digital health and real-world evidence.

**MODERATOR | Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition**

**Jesse Berlin**, Sc.D., Vice President and Global Head of Epidemiology, Johnson and Johnson

**Lauren Silvis**, J.D., Chief of Staff, Immediate Office of the Commissioner, FDA
4:55 pm   Engaging Everyone: Leveraging Diversity and Facilitating Equitable Access to Personalized Care

Advancing a medical paradigm that focuses on the unique characteristics of each patient will require, by definition, that patients from diverse backgrounds participate in the medical studies that advance our understanding of disease. Also critical is the need to ensure that those patients have access to personalized care informed by those studies. During this session, panelists will discuss the effort to ensure that all patient populations benefit equally from personalized medicine.

**MODERATOR | Donna R. Cryer**, J.D., President, CEO, Global Liver Institute

**Vence L. Bonham**, Jr., J.D., Senior Advisor to the Director of the U.S. National Human Genome Research Institute on Genomics and Health Disparities

**Alex J. Carlisle**, Ph.D., Chairman, CEO, National Alliance Against Disparities in Patient Health

**Adolph P. Falcón**, Executive Vice President, National Alliance for Hispanic Health

**Edward Tepporn**, Executive Vice President, Asian and Pacific Islander American Health Forum

5:55 pm   Closing Remarks

**SPEAKER | Amy Abernethy**, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health; Board member, Personalized Medicine Coalition

6:10 pm   Departure for the Museum of Fine Arts, Boston
WELCOME RECEPTION

AT THE BOSTON MUSEUM OF FINE ARTS

November 14, 2018 • 6:30 p.m. ET

Sponsored by

Intermountain Precision Genomics

BOSTON MUSEUM OF FINE ARTS • 465 HUNTINGTON AVE. • BOSTON, MA 02115
PART II
THE BUSINESS OF PERSONALIZATION

November 15, 2018

“The successful implementation of [personalized medicine] will depend on the embrace of [its] principles in the business community.”

— Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School
7:00 am  Registration and Breakfast

8:00 am  Opening Remarks

  SPEAKER  |  Stephen L. Eck, M.D., Ph.D.,
  Chief Medical Officer, Immatics US; Board
  Chair, Personalized Medicine Coalition

8:10 am  Pioneering Precision: Inside the
  Pharmaceutical Industry’s Push Toward
  Personalized Medicine — A Fireside Chat

  MODERATOR  |  Meg Tirrell, Reporter, CNBC
  Daniel O’Day, CEO, Roche Pharmaceuticals

8:55 am  Considering Costs: Evaluating Emerging
  Pharmaceutical and Insurance Industry
  Business Models in Personalized Medicine

  The pharmaceutical industry is deeply invested
  in commercializing personalized therapies that
  must recoup fixed development costs from
  smaller patient populations covered by health
  insurance companies that are increasingly
  concerned about rising health care costs. In
  that context, this diverse panel will explore the
  viability of the business model for developing
  and paying for personalized medicines, tackling
  issues related to costs, prices, and access.

  MODERATOR  |  Meg Tirrell, Reporter, CNBC
  Nick Leschly, CEO, bluebird bio
  Peter Juhn, M.D., Vice President, Global Head
  of Value-Based Partnerships, Amgen
  Michael Sherman, M.D., Chief Medical
  Officer, Senior Vice President, Harvard Pilgrim
  Health Care; Board member, Personalized
  Medicine Coalition
  Sean Tunis, M.D., Founder, CEO, Center
  for Medical Technology Policy; Board member,
  Personalized Medicine Coalition

9:55 am  Networking Break

10:25 am  Reinventing Research: Are Adaptive Platform
  Trials the Model of the Future? (A Harvard
  Business School Case Study)

  Recognizing that traditional randomized
  controlled clinical trials can only study the
  safety and efficacy of a single therapy in one
  large population of patients, researchers
  in personalized medicine increasingly hope
  that “adaptive platform trials,” which employ
  advanced statistical techniques to simul-
  taneously test the effectiveness of several
  personalized treatments in multiple sub-
  populations of patients, may be the key to
  new drug approvals in the future. Adaptive
  platform trials may make drug development
  more efficient by revealing which of several
  drug candidates are most promising for which
  patients, but maximizing the potential of
  these trials requires unprecedented collabo-
  ration among the institutions conducting and
  sponsoring research on various personalized
  treatments — and no obvious business models
  have emerged.

  During this interactive case study discussion,
  professors from Harvard Business School
  will help us examine how researchers at the
  Dana-Farber Cancer Institute considered and
  addressed myriad challenges in their effort
  to design and operationalize an adaptive plat-
  form trial for glioblastoma patients, a deadly
  disease state for which there are few existing
  treatment options.

  PRESENTED BY

  Richard Hamermesh, D.B.A., Co-Faculty Chair,
  Harvard Business School Kraft Precision
  Medicine Accelerator; and
  Ariel D. Stern, Ph.D., Assistant Professor,
  Technology and Operations Management Unit,
  Harvard Business School
11:40 am The 14th Annual Leadership in Personalized Medicine Award

INTRODUCTION | Steven D. Averbuch, M.D., Vice President, Head of Precision Medicine, Bristol-Myers Squibb; Board member, Personalized Medicine Coalition

AWARDEE | Ellen V. Sigal, Ph.D., Chairperson, Founder, Friends of Cancer Research

12:10 pm Bag Lunch

1:10 pm Predicting and Preventing: Evaluating Progress Toward Personalized Medicine

The original architects of the personalized medicine paradigm envisioned an era in which clinicians could predict, prevent and treat disease based on an improved understanding of how human biology interacts with external environments. During this session, a panel of experts will examine our progress on each of these fronts during a wide-ranging conversation about personalized medicine's past, present and future.

MODERATOR | Cynthia Casson Morton, Ph.D., William Lambert Richardson Professor of Obstetrics, Gynecology and Reproductive Biology, Professor of Pathology, Harvard Medical School; Kenneth J. Ryan, M.D., Distinguished Chair in Obstetrics and Gynecology, Brigham and Women’s Hospital

Birgit Funke, Ph.D., F.A.C.M.G., Vice President, Clinical Affairs, Veritas Genetics

Luba Greenwood, J.D., Strategic Business Development and Corporate Ventures, Verily (an Alphabet company)

Keith Stewart, M.B., CH.B., Carlson and Nelson Endowed Director, Center for Individualized Medicine, Mayo Clinic

2:10 pm Assessing the Assays: Determining the Clinical and Economic Utility of Genomic Sequencing

Advocates for personalized medicine have contended that genomic sequencing can deliver clinical and economic value to patients and the health system by allowing providers to more efficiently diagnose disease and develop treatment plans. Following increased use of genomic sequencing in clinical settings, many stakeholders, including payers, have begun to examine that value proposition more closely. During this session, a pharmaceutical industry representative, a payer, and a health economist will discuss the status and future of the emerging evidence regarding the clinical and economic utility of genomic sequencing, including studies recently commissioned by the Personalized Medicine Coalition.

MODERATOR | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition

Aris Baras, M.D., Vice President, Head, Regeneron Genetics Center, Regeneron Pharmaceuticals

Kristine Bordenave, M.D., F.A.C.P., Corporate Medical Director, Humana

Scott Ramsey, M.D., Ph.D., Full Member, Fred Hutchinson Cancer Research Center; Director, Hutchinson Institute for Cancer Outcomes Research

3:10 pm PhRMA Foundation Challenge Awards: Developing Value Assessment Strategies That Align With Personalized Medicine

INTRODUCTION | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition

PRESENTER | Shreeram Aradhya, M.D., Head of Global Medical Affairs, Chief Medical Officer, Pharmaceuticals, Novartis; Board member, PhRMA Foundation
3:20 pm  Networking Break

3:50 pm  Impasse or Inflection Point? — An Investment Analysis

Sustaining the pace of innovation in personalized medicine will require continued investment in new initiatives, but the financial outlook for the field remains unclear. In that context, this panel of investors will examine whether personalized medicine is at an impasse, an inflection point, or somewhere in between.

MODERATOR | William A. Sahlman, Ph.D., Baker Foundation Professor, Harvard Business School

Gregory Dorn, M.D., President, Hearst Health

Cary Pfeffer, M.D., Partner, Third Rock Ventures

Michael Pellini, M.D., Managing Partner, Section 32; Board member, Personalized Medicine Coalition

Salveen Richter, C.F.A., Vice President, Research Division, Goldman Sachs

4:50 pm  Closing Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition
Speakers

Amy Abernethy, M.D., Ph.D.
Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health; Board member, Personalized Medicine Coalition

Amy P. Abernethy, M.D., Ph.D., is the Chief Medical Officer and Chief Scientific Officer at Flatiron Health, a health care technology and services company focused on accelerating cancer research and improving patient care. She is a hematologist/oncologist and palliative medicine physician, as well as an internationally recognized cancer clinical researcher with more than 400 publications.

Dr. Abernethy is an appointee to the National Academy of Medicine’s National Cancer Policy Forum, is on the Executive Board for the Personalized Medicine Coalition, and is Past President of the American Academy of Hospice & Palliative Medicine. Before joining Flatiron, Dr. Abernethy was Professor of Medicine at Duke University School of Medicine, where she directed the Center for Learning Health Care in the Duke Clinical Research Institute and the Duke Cancer Care Research Program in the Duke Cancer Institute. She is also on the Board of Directors of athenahealth, Inc., and was featured on TEDMED in 2013.

Edward Abrahams, Ph.D.
President, Personalized Medicine Coalition

Edward Abrahams, Ph.D., is the President of PMC. Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products for the benefit of patients and the health system. It has grown from its original 18 founding members in 2004 to more than 225 today.

Previously, Dr. Abrahams was the Executive Director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University.

The author of numerous essays, Dr. Abrahams has taught history and public policy at Brown University and the University of Pennsylvania.
**Antonio L. Andreu, M.D., Ph.D.**  
**Scientific Director, EATRIS European Infrastructure for Translational Medicine**

Toni is an M.D., Ph.D. who specialized in genetics and genomics of rare diseases. He has been working in the field of neuromuscular disorders from the translational perspective of the pipeline, from basic science to the development of cell and animal models and clinical research.

After working at Columbia University in New York on mitochondrial disorders from 1998 to 2001, he moved to Barcelona to create the Neuromuscular Lab at the Vall d’Hebron Research Institute, where he became Director of the Neurosciences Research Program.

He has also been extremely active in the field of policymaking and has held positions as the Director of the Spanish National Institute of Health Carlos III, creating the national program for personalized medicine. He has also been the CEO of the Bellvitge Hospital, one of the most important University hospitals in Spain, as well as the Director General for Research and Innovation at the Catalan Ministry of Health.

Toni is now the Scientific Director at EATRIS European Advanced Infrastructure for Translational Research.

**Shreeram Aradhye, M.D.**  
**Head of Global Medical Affairs, Chief Medical Officer, Pharmaceuticals, Novartis; Board member, PhRMA Foundation**

Shreeram Aradhye has been Novartis’ Global Head, Medical Affairs, and Chief Medical Officer, Pharmaceuticals, since February of 2017. He is a member of the Pharma Executive Committee and a member of the Development Committee.

Prior to his current appointments, Shreeram served as Global Head, Development, Neuroscience, for more than three years, after serving as Executive Global Program Head for the multiple sclerosis portfolio from 2012 to 2013 and Head of Global Development in India from 2011 to 2012. Prior to that, Aradhye held multiple leadership roles, including Head, U.S. Medical Affairs; Head, Global Medical Affairs for Transplantation and Immunology; Senior Global Program Medical Director for Gilenya; and Clinical Franchise Head for the Immunology and Infectious Diseases Franchise.

Before joining Novartis, Aradhye was an Assistant Professor of Medicine and transplant nephrologist at the University of Pennsylvania, Philadelphia.
**Aris Baras, M.D., M.B.A.**

Vice President, Head, Regeneron Genetics Center, Regeneron Pharmaceuticals

Dr. Baras serves as Vice President, Regeneron Pharmaceuticals and Head of the Regeneron Genetics Center (RGC), one of the largest human genetics programs in the world, spanning large-scale sequencing, informatics, and translational sciences using human genetics to advance and guide the development of Regeneron’s pipeline of important new medicines. He has established and leads several foundational genomics collaborations, such as with the Geisinger Health System to sequence at least 250,000 participants and with the U.K. Biobank to sequence 500,000 participants.

The RGC has produced many high-impact discoveries identifying new drug targets (such as HSD17B13 in chronic liver diseases), validating existing development programs (Regeneron’s evinacumab program targeting ANGPTL3, REGN3500 targeting IL33, and many more), and contributing important new gene discoveries and precision medicine strategies. The RGC has sequenced more than 300,000 individuals to date, collaborating with more than 60 institutions around the world, and plans to sequence the genomes of millions of participants across its studies.

Previously, Dr. Baras held roles and responsibilities at Regeneron across R & D and business development. Prior to Regeneron, Dr. Baras contributed to other biotechnology ventures and conducted research spanning antibody-based therapeutics, cancer research, and nanotechnology applications in drug development. Dr. Baras received his bachelor’s of science, M.D. and M.B.A. all from Duke University.

**Steven D. Averbuch, M.D.**

Vice President, Head of Precision Medicine, Bristol-Myers Squibb; Board member, Personalized Medicine Coalition

Dr. Averbuch is Vice President and Head, Precision Medicine, within the Translational Medicine Division of R&D at Bristol-Myers Squibb. In this role, he leads integrated biomarker and pharmacodiagnostic activities across the BMS R&D portfolio.

Dr. Averbuch joined Bristol-Myers Squibb in 2006 and has led the Pharmacodiagnostics Center of Excellence since 2008. Other previous roles include: leading the strategy, business development agreements and execution of external clinical collaborations for the company’s immuno-oncology pipeline; executive sponsor and oversight for translational research activities for all late development and marketed oncology compounds; leader of corporate-wide strategic initiatives for Translational and Targeted Medicine; co-leader of the oncology early strategy team, which included responsibility for the execution of Phase 2 oncology programs.

Dr. Averbuch has made significant contributions to business development and has participated in multiple successful licensing and acquisition deals.

He previously held positions at Merck Research Laboratories, AstraZeneca and Mount Sinai School of Medicine. He received his M.D. and internal medicine training from the University of Illinois, Chicago, and his medical oncology training at the National Cancer Institute in Bethesda, Maryland.
Cynthia A. Bens
Senior Vice President, Public Policy, Personalized Medicine Coalition

Cynthia A. Bens, Senior Vice President, Public Policy, PMC, leads the Coalition’s policy development and government relations efforts and serves as its primary liaison with the U.S. Congress and federal regulators. In collaboration with PMC’s Senior Vice President, Science Policy, Bens is responsible for implementing research, regulatory, and reimbursement policy strategies that promote the understanding and adoption of personalized medicine concepts, services, and products to benefit patients and the health system.

Before joining PMC, Bens was the Vice President of Public Policy at the Alliance for Aging Research. Bens guided the Alliance’s federal policy work, represented the organization in multiple national coalitions, and directed all aspects of coalitions led by the Alliance. She spent more than a decade at the Alliance advancing policies to expedite the development of interventions for neurological diseases and physical frailty; to remove access barriers for cardiovascular disease treatments; and to enhance the quality of care for older adults living with multiple chronic conditions.

Jesse Berlin, Sc.D.
Vice President and Global Head of Epidemiology, Johnson and Johnson

Dr. Berlin received his doctorate in biostatistics from the Harvard School of Public Health in 1988. After spending 15 years as a faculty member at the University of Pennsylvania, in the Center for Clinical Epidemiology and Biostatistics, Jesse left Penn to join Janssen Research & Development in Biostatistics. He now serves as Vice President and Global Head of Epidemiology across Johnson & Johnson, responsible for pharmaceuticals, devices and consumer products. He has co-authored over 270 peer-reviewed publications in a variety of clinical and methodological areas, including papers on the study of meta-analytic methods for both randomized trials and epidemiology. He served on an Institute of Medicine Committee that developed recommendations for the use of systematic reviews in clinical effectiveness research, and served as Chair of the Scientific Advisory Committee to IMEDS (Innovation in Medical Evidence Development and Surveillance), part of the Reagan-Udall Foundation.

Dr. Berlin co-chairs the Scientific Oversight Committee (with Greg Pappas from FDA) for MDEpiNet, a public-private partnership that is working toward developing methods and data sources for the evaluation of medical devices. Dr. Berlin served as an editorial team member of working group X for CIOMS (The Council for International Organizations of Medical Sciences), which has published guidelines for meta-analysis of drug safety data in the regulatory context. He was elected as a fellow of the American Statistical Association in 2004. In 2013, Dr. Berlin received the Lagakos Distinguished Alumni Award from the Department of Biostatistics at the Harvard School of Public Health.
Vence L. Bonham, Jr., J.D.
Senior Advisor to the Director of the U.S. National Human Genome Research Institute on Genomics and Health Disparities

Vence Bonham received his bachelor of arts from James Madison College at Michigan State University and his juris doctor degree from the Moritz College of Law at the Ohio State University. Mr. Bonham was a tenured faculty member at Michigan State University in the College of Human Medicine and adjunct professor in the Michigan State University College of Law.

Since 2003, Mr. Bonham has served as an investigator in the National Human Genome Research Institute (NHGRI) within the Division of Intramural Research’s Social and Behavioral Research Branch. He leads the Health Disparities Genomics Unit, which conducts research that evaluates approaches to integrating new genomic knowledge and precision medicine into clinical settings without exacerbating inequities in health care delivery. His research focuses primarily on the social influences of new genomic knowledge, particularly in communities of color. He studies how genomics influences the use of the constructs of race and ethnicity in biomedical research and clinical care and the role of genomics in health inequities.

Mr. Bonham also serves as the Senior Advisor to the Director of the NHGRI on Genomics and Health Disparities.

Kristine Bordenave, M.D., F.A.C.P.
Corporate Medical Director, Humana

Kristine Bordenave, M.D., F.A.C.P., is a Corporate Medical Director overseeing Humana’s National Medicare/Medicaid Clinical Review Expertise Team. Board-certified in internal medicine, she is driven to ensure efficient, high-quality resources to support the health of present and future generations. She has a particular interest in integration/collaboration opportunities supporting sustainable maximization of scope and/or scale while improving clinical and financial outcomes. She is a member of several organizations and has multiple publications/presentations related to chronic disease, systems redesign and population genetics.
Alex J. Carlisle, Ph.D.
Chairman, CEO, National Alliance Against Disparities in Patient Health

Dr. Alex Carlisle holds a doctorate in biochemistry and molecular biology from Howard University and has spent the past 17 years developing and applying translational and clinical research approaches in the areas of molecular oncology and neuroscience. Dr. Carlisle received his post-doctoral training at the U.S. National Institutes of Health, where he served at the National Cancer Institute as a leading member of the Cancer Genome Anatomy Project, and at the National Institute for Neurological Disorders and Stroke.

Dr. Carlisle went on to Fox Chase Cancer Center and later joined the Children’s Hospital of Philadelphia. Dr. Carlisle then moved to Inova Fairfax Hospital, serving as the Department of Neuroscience’s first Principal Investigator for the Inova-George Mason University Neuroscience Translational Research Laboratory. At Inova, he served as Director of the Laboratory of Neuro-Oncology, where he directed research programs in neuroblastoma and traumatic brain injury. He continues to serve as an Affiliate Professor of Molecular Neuroscience at George Mason University’s Krasnow Institute.

Donna R. Cryer, J.D.
President, CEO, Global Liver Institute

Donna R. Cryer, J.D., has channeled her personal experience as an IBD and liver transplant patient into professional advocacy as President and CEO of the Global Liver Institute, the innovation and collaboration platform for the liver community. Ms. Cryer most recently served as Chair, President and CEO of the American Liver Foundation, the largest and oldest national nonprofit organization serving liver disease patients and their families. She was the first patient to lead the organization in its 36-year history.

For eight years, Ms. Cryer has led CryerHealth, a health care consulting firm providing strategic counsel to top biopharmaceutical companies, patient advocacy organizations and emerging technology firms on patient engagement in health information technology, drug discovery, and clinical decision-making.
William S. Dalton, Ph.D., M.D.
Founder, Executive Chairman, M2Gen; Board member, Personalized Medicine Coalition

Dr. William (Bill) S. Dalton is Founder and Executive Chairman of M2Gen, a national biotechnology subsidiary of Moffitt Cancer Center. He is the past President, CEO & Center Director of Moffitt Cancer Center, an NCI-Designated Comprehensive Cancer Center (2002–2012). Prior to joining Moffitt, Dr. Dalton was the Dean of the University of Arizona College of Medicine. His research interests include development of information systems to allow aggregation, organization, and sharing of patient data in real time to enhance the discovery and delivery of evidence-based precision medicine.

While at Moffitt, he participated in the development of the “Total Cancer Care Protocol” designed to follow patients throughout their lifetime, with patients donating their clinical data, tissue, and molecular data to support precision medicine. In 2014, the Moffitt Cancer Center partnered with the James Cancer Center at the Ohio State University to form ORIEN, an alliance of 18 cancer centers dedicated to data sharing and collaborative research. For his leadership in the area of personalized medicine, Dr. Dalton was recognized as the 2010 recipient of the Personalized Medicine Coalition’s National Leadership in Personalized Medicine Award. Dr. Dalton’s basic and translational research interests focus on molecular mechanisms of drug resistance and drug discovery. He has over 200 publications, serves on several editorial boards, and has numerous patents in the fields of drug discovery and computer/information networking.

Ora Dar, Ph.D.
Senior Expert, National Research and Development Projects, Technological Infrastructure Division, Israel Innovation Authority

Dr. Ora Dar has 16 years of technological and operational experience, including 13 years (2005–2018) of senior management positions as the head of the Life Sciences sector at Israel Innovation Authority (formerly the Office of the Chief Scientist, the Israeli Ministry of Economy). She currently serves as leader of National Infrastructure Platforms for Biotech R&D.

Dr. Dar initiated and implemented tools and new incentive platforms required for advancing R&D in life sciences companies and for enhancing the technology transfer between academia and industry.

Currently, Dr. Dar is among the leaders of the National Genomic and Personalized Medicine Initiative, which involves the establishment of a national research-oriented genomic-clinical database of 100,000 volunteers.

Prior to joining the Office of the Chief Scientist, Dr. Dar spent 16 years in academic research and served 10 years as a consultant to local and global venture capital and investment firms.
Michael Doherty
Senior Vice President, Head of Product Development, Head of Research and Development, Foundation Medicine

Michael Doherty joined Foundation Medicine in January of 2017 as Head of Product Development, and has served as Head of R&D since January of 2018. Prior to joining the company, Mr. Doherty was Head of Regulatory Affairs at Roche Pharmaceuticals and Genentech for a period of 14 years from 2002 to 2016, overseeing the approvals of products in the fields of oncology, immunology, hematology and bone disease. Prior to Roche Pharmaceuticals and Genentech, he worked in regulatory affairs at pharmaceutical companies based in the U.K., France, Switzerland and the U.S. Doherty serves as Regulatory Strategy Adviser to VisionGate, a clinical-stage cancer diagnostics and therapeutics company, and as a member of the Board of Monarch BioNetworks.

Mr. Doherty has a B.Sc. in biochemistry from the University of Reading and a diploma in management studies from the University of Portsmouth, in the U.K.

Gregory Dorn, M.D.
President, Hearst Health

Greg Dorn is a Senior Vice President of Hearst and the President and Group Head of Hearst Health, overseeing Hearst’s health care businesses in the U.S. and globally, including FDB (First Databank), Zynx Health, MCG, Homecare Homebase, MedHOK, Hearst Health Ventures, and the Hearst Health Innovation Lab. He also serves as a Director of M2Gen.

For more than two decades, Dorn has been focused on raising the standard of excellence for patient care across the health care spectrum through clinically rigorous guidance delivered by efficient, scalable technology. He is the co-inventor of two patented health care software technologies that continue to be used in health systems across the U.S.

Dorn has held a variety of leadership positions across Hearst, including Chief Operating Officer of Zynx Health and President of FDB. In 2013, he was appointed a Vice President of Hearst to lead its growing portfolio of health care companies. He became President of Hearst Health in 2014. Each year in the U.S., care guidance from Hearst Health reaches 85 percent of discharged patients and 205 million insured individuals. It also accounts for 70 million home health visits and 3.2 billion dispensed prescriptions.

Dorn received his medical doctorate from the Columbia University College of Physicians and Surgeons and his bachelor’s degree from the Columbia University School of Engineering. He performed his clinical training at UCLA, where he also obtained his master’s degree in health services management.
Stephen L. Eck, M.D., Ph.D.
Chief Medical Officer, Immatics US; Board Chair, Personalized Medicine Coalition

Dr. Eck has over 15 years of leadership experience in the development of oncology drugs and related biomarkers. He has served as Vice President of Oncology Medical Sciences at Astellas Pharma Global Development, Inc. Previous to that, he served as Vice President, Translational Medicine & Pharmacogenomics at Eli Lilly and Company, where his group developed the biomarkers and companion diagnostics needed for study-specific decision making and for tailoring biotherapeutics to unique patient populations. Prior to joining Lilly, he served in a variety of oncology and neuroscience drug development leadership roles at Pfizer, Inc.

Dr. Eck is a Board-certified hematologist who holds a Ph.D. in chemistry from Harvard University and received his M.D. from the University of Mississippi School of Medicine. He serves on the Board of Directors of Luminex Corporation and is a Fellow of the American Association for the Advancement of Science. He is also a member of the University of Texas MD Anderson Cancer Center President’s Advisory Board for the Moonshot Program.

Adolph P. Falcón, M.P.P.
Executive Vice President, National Alliance for Hispanic Health

As the Executive Vice President of the National Alliance for Hispanic Health, Adolph Falcón provides leadership and management for the Alliance’s program portfolio and development efforts. He also oversees the science and policy portfolio of the Alliance, including serving as Director of the Alliance’s Healthy Americas Institute at the University of Southern California Keck School of Medicine.

A nationally recognized expert on Hispanic health policy, he played a leading role in the landmark Disadvantaged Minority Health Improvement Act of 1990 and most recently has been active in the Children’s Health Insurance Program Reauthorization Act, Sugar-Sweetened Beverages Tax Act, Personal Care Products Safety Act, and regulatory efforts to improve the quality of health care.
Joseph V. Ferrara
CEO, Boston Healthcare Associates

Mr. Ferrara has over 20 years of experience in life sciences consulting, working with biopharmaceutical, medical device, diagnostics, and health care IT clients in market and business development strategy. He leads the global consulting team with practice areas in reimbursement and pricing, health economics, market analysis, and business development strategy. Mr. Ferrara has extensive experience in the development of novel business approaches designed to capture evidence-based value for innovative health care technologies. Mr. Ferrara writes and speaks extensively on the subject of the value of medical technology innovation, with a particular focus on pharmacogenomics, specialty pharmaceuticals, and novel therapeutic devices.

Prior to his consulting role, Mr. Ferrara led a joint venture between Boston Healthcare and a nonprofit research organization focused on a global electronic medical record network for the purposes of clinical trials and health outcomes research.

Mr. Ferrara completed undergraduate studies at the University of Cincinnati and received a master’s degree from Harvard University.

Tom Fowler, Ph.D.
Deputy Chief Scientist, Director of Public Health, Genomics England

Dr. Tom Fowler is Genomics England’s Director of Public Health and Deputy Chief Scientist. In this capacity, Tom works to support the team around rare diseases, infectious diseases and cancer. In particular, he has led the rare disease pilot phase of the 100,000 Genomes Project. He also coordinates the Project’s infectious disease strand, which is led primarily by Public Health England.

After obtaining a Ph.D. in behavioural genetics in 2003, his career began as a Specialist Registrar in Public Health, working in the NHS. He has worked in both commissioning and specialised commissioning and held roles such as regional epidemiologist and health protection consultant.

As a locum Public Health consultant at the Chief Medical Officer’s Private Office from 2011–2013, Tom was Editor-in-Chief of the Annual State of the Public’s Health (Vol. I), a comprehensive review of health data for England. During this time, Tom worked with the Chief Medical Officer of England on thought leadership around public health, including wellness and antimicrobial resistance. Tom was a member of the Public Health Genomics European Network (PHGEN) meeting that led to the Declaration of Rome 2012 summary of the European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies.
Luba Greenwood, J.D.
Strategic Business Development and Corporate Ventures, Verily (an Alphabet Company)

Luba brings to Verily pharmaceutical, biotechnology, and digital health industry experience and expertise in building and advising innovative technology companies and providing strategic counsel to global corporations. Previously, Luba has served as Vice President of Global Business Development and Mergers & Acquisitions at Roche, where she also established and led the East Coast Innovation Hub for the Diagnostics Division. Luba is on the Board of MassBio and IRX Therapeutics, and serves as Advisor to Dana-Farber Cancer Institute, as part of its Business Development Council. She is also a lecturer at Boston University Law School and School of Management, where she has taught courses in life sciences, business law, innovation, and entrepreneurship since 2014.

Luba’s career has spanned leadership roles in venture investing, business development, mergers & acquisitions, law, and operations. Luba began her career practicing law at a leading national law firm, Wilmer Cutler Pickering Hale and Dorr, where she represented clients in securities, intellectual property, regulatory, corporate and litigation matters.

Luba is a recipient of several awards and honors for her work in the community, including the Science Club for Girls Catalyst Award for her commitment to advocating for women in science and technology. Luba served as nonprofit Board member of Longwood Symphony Orchestra, Executive Coach for MassNextGen, Co-Chair of MassBio’s Entrepreneur’s University, and Mentor and Judge for MassCONNECT, MIT 100K Entrepreneurship Competition, and MassChallenge.

Birgit Funke, Ph.D., F.A.C.M.G.
Vice President, Clinical Affairs, Veritas Genetics

A board-certified clinical molecular geneticist, Funke is also an Associate Professor of Pathology at Harvard Medical School.

In her role at Veritas, Dr. Funke works with a team of over 100 people made up of curators, bioinformaticians and developers to streamline the company’s interpretation process, implement automation, and deliver actionable clinical insights to consumers (and their physicians) around the world.
Richard Hamermesh, D.B.A.
Co-Faculty Chair, Harvard Business School
Kraft Precision Medicine Accelerator

Richard Hamermesh is a Senior Fellow at the Harvard Business School, where he was formerly the MBA Class of 1961 Professor of Management Practice. Currently, Richard is the Faculty Co-Chair of the Kraft Precision Medicine Accelerator. Richard created and teaches the second-year MBA elective, Building Life Science Businesses. Previously, he was the course head for the required first-year course, The Entrepreneurial Manager.

From 1987 to 2001, Richard was a Co-Founder and a Managing Partner of The Center for Executive Development, an executive education and development consulting firm. Prior to this, from 1976 to 1987, he was a member of the faculty of the Harvard Business School.

Richard is also an active investor and entrepreneur, having participated as a principal, director and investor in the founding and early stages of more than 20 organizations. He was the founding president of the Newton Schools Foundation and served on the editorial board of the Harvard Business Review.

Richard is the author or co-author of five books, including New Business Ventures and The Entrepreneur. His best-known book, Fad-Free Management, was published in 1996. He has published more than 100 case studies and numerous articles, including his recent publications “What Precision Medicine Can Learn from the NFL” and “One Obstacle to Curing Cancer: Patient Data Isn’t Shared.”

Colin Hill
Chairman, CEO, Co-Founder,
GNS Healthcare

Colin Hill is a leading voice in machine learning in health care and precision medicine. He co-founded GNS Healthcare in 2000 and has since served as Chairman and CEO. Colin sits on the Board of Biotelemetry, Inc. (NASDAQ: BEAT), a leading mobile health information company, and PPD, a leading global contract research organization. Colin was a founding member of the Board of Directors of AesRx (acquired by Baxter in 2014). In 2004, Colin was named to MIT Technology Review’s list of the top 100 innovators in the world under the age of 35.
Peter Juhn, M.D., M.P.H.
Vice President, Global Head of Value-Based Partnerships, Amgen

Dr. Peter Juhn is Vice President and Global Head of Value-Based Partnerships at Amgen. He is responsible for implementing partnerships with payers, care delivery organizations and other key health care stakeholders that can lead to more clinical improvement opportunities for patients with serious and debilitating illnesses and result in greater overall value for the health care system.

Most recently, he was Vice President for Integrated Care Services in the Global Diabetes Division at Sanofi, where he was responsible for creating new patient service platforms and their attendant new business models. He led the business planning efforts for the Sanofi joint venture in diabetes with Verily (aka Google Life Sciences).

Prior to Sanofi, he was at Medco Health Solutions (at the time, the largest pharmacy benefit manager with 65 million enrollees) as President of the Therapeutic Resource Centers division, leading a team of over 1,000 pharmacists providing medication management support to Medco’s members, and then as Chief Medical Officer of Medco International, where he led the delivery of medication support programs for clients in the U.K., Germany, Sweden and the Netherlands.

Julie Khani, M.P.A
President, American Clinical Laboratory Association

Julie Khani became President of the American Clinical Laboratory Association (ACLA) in 2017. She joined ACLA in July of 2013 as Senior Vice President and was named Executive Vice President in 2016.

Khani leads ACLA’s efforts to advance public policies that promote innovation and protect and enhance patient access to life-improving and life-saving diagnostics. ACLA members represent the diversity of the clinical laboratory industry and include national, regional, specialty, hospital, ESRD, anatomic pathology, skilled nursing facility and academic medical center laboratories.

Ms. Khani is recognized as an effective leader, consensus builder and advocate. Prior to joining ACLA, she served in senior roles at the National Association of Chain Drug Stores (NACDS). She was instrumental in the inclusion of pharmacy access standards in Medicare Part D, establishing incentives for TRICARE beneficiaries to obtain immunizations at retail pharmacies, and the implementation of the Affordable Care Act provisions on Medicaid reimbursement for generic drugs.

Previously, Khani served as Legislative Manager at Ford Motor Company, where she was responsible for health and labor issues and the company’s political action committee. Ms. Khani was also Associate Director, Government Relations, at Planned Parenthood Pennsylvania Advocates, where she managed several successful statewide campaigns on health and welfare issues. She holds a bachelor of arts from New York University and a master of public administration from George Washington University.
David P. King, J.D.
Chairman, CEO, LabCorp

David King, J.D., is the Chairman and CEO of Laboratory Corporation of America Holdings (LabCorp), one of the world’s largest networks of clinical laboratories. Prior to joining LabCorp in 2001, Mr. King worked for many years as the company’s outside counsel as a partner with Hogan & Hartson LLP (now Hogan Lovells) in Baltimore, Maryland.

Mr. King sits on the Board of Cardinal Health, Inc., a Fortune 100 health care company. He also chairs the Board of the American Clinical Laboratory Association and serves on the Board of the Seattle Science Foundation.

Emily Kramer-Golinkoff, M.B.E.
Co-Founder, Emily’s Entourage; cystic fibrosis patient

Emily Kramer-Golinkoff is Co-Founder of Emily’s Entourage, a 501(c)3 that accelerates research for new treatments and a cure for cystic fibrosis. She is also an internationally recognized patient advocate and speaker.

Named a “Champion of Change” for President Obama’s Precision Medicine Initiative, Emily’s Entourage has awarded over $3.4 million in research grants since 2011, leading worldwide efforts to fast-track research and drug development on nonsense mutations in cystic fibrosis. The organization has been featured on CNN, Time.com, People.com and more.

Emily has a master’s degree in bioethics and certification in clinical ethics mediation from the University of Pennsylvania, where she also completed her undergraduate degree.
Marc LePage
President, CEO, Genome Canada

Marc LePage is President and CEO of Genome Canada. Before assuming this role in January of 2016, he served as President and CEO of Génome Québec since December 2011, where he led a major increase in research activity and enhanced focus on the development of genomic applications within priority sectors in the province.

He brings a wealth of experience in the innovation sector and venture capital, in addition to a broad network of international contacts. He is an expert in international partnerships and previously served as Special Advisor, Climate Change and Energy, for the Embassy of Canada in Washington, D.C., and worked as Consul General at the Canadian Consulate in San Francisco/Silicon Valley.

Marc LePage was also one of the pioneers behind the founding of Genome Canada in 2000. During his tenure as Executive Vice President of Corporate Development, he made a significant contribution to the development of genomics in Canada.

From 1994 to 2000, he worked as Director of Business Development for the Medical Research Council, where he was in charge of building international partnerships with the pharmaceutical industry, venture capital and foundations.

Nick Leschly, M.B.A.
CEO, bluebird bio

Nick Leschly has served as CEO of bluebird since September of 2010. Formerly, Nick was a Partner and Founding Member of Third Rock Ventures in 2007. Nick played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc., and Edimer Pharmaceuticals, Inc.

Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs, and served as the product leader for VELCADE. Nick also founded and served as the CEO of MedXtend Corporation. He received his B.S. in molecular biology from Princeton University and his M.B.A. from Wharton Business School. He currently serves as a Board member of the Biotechnology Innovation Organization (BIO), Synlogic and Proclara Biosciences.
Susan McClure  
Founder, Publisher, Genome magazine; Board member, Personalized Medicine Coalition

Susan brought 30 years of journalistic experience to her role as Publisher for Genome magazine — the first consumer magazine exclusively devoted to personalized medicine and genomics.

Prior to the launch of Genome, she spent 10 years as the publisher of CURE — a magazine for cancer patients, survivors and caregivers. During her tenure at CURE, she also served as Vice President of Patient Engagement for McKesson Specialty Health.

In 2016, Susan was honored by Folio as one of the “Top Women in Media” for her entrepreneurial efforts in magazine publishing and media. She has over 20 years of experience delivering first-class sales and management strategies to leading and start-up media and health care organizations, and is especially skilled at creating collaborative partnerships that result in highly respected educational offerings for patients and health care providers.

Tom Miller  
Managing Partner, GreyBird Ventures LLC

After earning a graduate degree from the Harvard/MIT Health Sciences and Technology program, Tom joined Siemens, where he ran the global MRI business. He has also served as the CEO of the global medical operations of Carl Zeiss, the CEO of Analogic Corporation, and Chairman and CEO of LightLab Imaging, a start-up he helped to establish and sell. Tom re-joined Siemens in 2002, serving as a member of the Global Operating Board and Division CEO of Siemens Healthcare, with 26,000 employees in over 130 countries. In 2013, Tom started GreyBird Ventures, an investment firm focused on technologies for precision medicine diagnosis. Tom is a speaker on health care technology at conferences around the world and serves as director or chairman on the boards of five medical technology companies.
Cynthia Casson Morton, Ph.D.
William Lambert Richardson Professor of Obstetrics, Gynecology and Reproductive Biology, Professor of Pathology, Harvard Medical School; Kenneth J. Ryan, M.D., Distinguished Chair in Obstetrics and Gynecology, Brigham and Women’s Hospital

Cynthia Casson Morton received her bachelor’s of science degree from the College of William and Mary in Virginia and her Ph.D. in human genetics from the Medical College of Virginia in Richmond. Dr. Morton is certified by the American Board of Medical Genetics in Ph.D. Medical Genetics, Clinical Cytogenetics and Clinical Molecular Genetics. Her research interests are in molecular cytogenetics, hereditary deafness, genetics of uterine leiomyomata, and human developmental disorders. She has published over 300 original articles.

As Director of Cytogenetics at BWH, Dr. Morton has implemented the use of next-generation sequencing to provide nucleotide resolution of balanced chromosomal rearrangements detected in the prenatal setting. Her laboratory has been a major site for training laboratory geneticists in clinical cytogenetics.

Dr. Morton served as President of the American Society of Human Genetics in 2014. She was a member of the Board of Directors of the Society and completed a six-year tenure as editor of its journal, The American Journal of Human Genetics. She is currently Co-Editor of Human Genetics. Dr. Morton also is a past member of the Board of Directors of the American Board of Medical Genetics, where she served as Secretary, Treasurer and Chair of the Accreditation Committee. She was previously the Chair of the Molecular Genetic Pathology Policy and Exam Committees of the American Board of Medical Genetics and the American Board of Pathology.

Elizabeth Nabel, M.D.
President, Brigham Health

Betsy Nabel has served as President of Harvard-affiliated Brigham Health — an academic health care system which includes Brigham and Women’s Hospital, Brigham and Women’s Faulkner Hospital, and the Brigham and Women’s Physician Organization — since 2010. A cardiologist and distinguished biomedical researcher, Nabel is Professor of Medicine at Harvard Medical School.

Nabel brings a unique perspective to health care based on her experience as a physician, research scientist, academic medicine leader and wellness advocate. At Brigham Health, Nabel is leading development of a new model of academic medicine devoted to maintaining and restoring health through leadership in scientific discovery, education and compassionate care. Initiatives include a new translational research and clinical facility, leading-edge care redesign and a $1.5 billion campaign to advance life-giving breakthroughs.

Nabel has a long record of advocacy for health and broadening access to care. As Director of the National Heart, Lung, and Blood Institute from 2005–2009, Nabel leveraged the $3 billion research portfolio to establish pioneering scientific programs in genomics, stem cells, and translational research. One of her signature advocacy efforts was the Red Dress Heart Truth campaign, which raises heart awareness in women through unprecedented industry partnerships.
Bryce Olson is the Global Marketing Director for Intel’s Health and Life Sciences group. One of the areas he focuses on is bringing technology and science together in the exciting area of genomics and precision medicine with a powerful message on how this saves lives. Genomic sequencing and precision medicine gave him a life he didn’t think he’d get to live.

Bryce is inspired by connecting the advances in life sciences to clinical settings and helping patients understand these new opportunities. He is a sought after keynote speaker both locally and nationally, and his story has been covered by both local and national media. Bryce also started FACTS (Fighting Advanced Cancer Through Songs), a movement that uses the power of music to build awareness for a new way to fight cancer and bring molecular testing and precision medicine to other advanced cancer patients. In 2017, Bryce wrote and co-produced a rock-n-roll album, with proceeds going towards the FACTS movement, that brought together a variety of Portland, Oregon based musicians and singers including Jenny Conlee from the Decemberists, Martha Davis from the Motels, Pete Krebs and Michelle DeCourcy — all four of whom are also cancer survivors.

Daniel O’Day, M.B.A.
CEO, Roche Pharmaceuticals

Daniel O’Day is the CEO of Roche Pharmaceuticals and a member of the Roche Corporate Executive Committee.

Daniel has been in his current role since 2012, and previously served as CEO of Roche Diagnostics. His global career spans three decades of diverse leadership roles across North America, Asia Pacific and Europe.

After joining Roche Pharmaceuticals in 1987, Daniel held various roles in the U.S. before moving to Roche headquarters in Switzerland in 1998. During his time there, he held leadership roles in Global Marketing and Lifecycle Management. In 2001, Daniel’s career took him to Tokyo, where he was Head of Corporate Planning for Roche Pharma in Japan, and later to Denmark, as General Manager.

Daniel became President of Roche Molecular Diagnostics in California in 2006, and subsequently returned to Roche headquarters to lead the Diagnostics Division.

Daniel holds a bachelor’s of science in biology from Georgetown University in Washington, D.C., and an M.B.A. from Columbia University in New York.
Cary Pfeffer, M.D.
Partner, Third Rock Ventures

Cary Pfeffer joined Third Rock Ventures at its inception in 2007 and has more than 20 years of business development and transaction experience, along with a broad array of biotech product development experience. Cary leads Third Rock’s partner development efforts, including building and maintaining strong relationships to work with large biotech and pharmaceutical companies. He has played an instrumental role in a number of innovative alliances and collaborative company building efforts across our portfolio, including an industry-leading global strategic collaboration between Agios and Celgene in the field of cancer metabolism.

Cary supports and advises on business development efforts across our portfolio and has also assumed active leadership roles in our portfolio companies, functioning as CEO and chief business officer through the first 12–18 months after launch.

Before joining Third Rock, Cary founded The Pfeffer Group, a boutique consulting firm that provided business development and strategy advisory services, completing multiple transactions for leading biotechnology and life sciences companies. Prior to that, Cary spent more than a decade at Biogen, where he held a variety of senior and executive level U.S. and global management roles focused on business and market development, product development, and commercial operations.

Michael Pellini, M.D., M.B.A
Managing Partner, Section 32; Board member, Personalized Medicine Coalition

Dr. Pellini is Managing Partner of Section 32, a venture fund that invests in companies and inventors that are changing the way humans use technology and the way technology betters humanity. Previously, he served as CEO of Foundation Medicine (NASDAQ:FMI) from May of 2011 until he transitioned to Chairman in February of 2017.

He currently serves as a member of the Board of Directors for Tango Therapeutics, Singular Genomics, Adaptive Biotechnologies, Octave Health, Vineti, the Personalized Medicine Coalition, and the Mission Hospital Foundation, in addition to holding his Board Chair position with Foundation Medicine. As a physician with more than 20 years of executive experience with companies at the forefront of clinical diagnostics and genomics, Dr. Pellini brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer. Dr. Pellini is a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health, as well as the Advisory Board for Mission Hospital’s Cancer Institute (Provident/St. Joseph Health).

Dr. Pellini received a B.A. from Boston College, an M.B.A. from Drexel University, and an M.D. from Jefferson Medical College.
Kimberly Popovits  
Chairman of the Board, CEO, President, Genomic Health; Board member, Personalized Medicine Coalition

Committed to changing the paradigm of cancer care, Kim Popovits has led Genomic Health in revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon and prostate cancers that address the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in health care today. Kim has served as Genomic Health’s Chairman of the Board since 2012, and CEO and President since 2009.

Prior to joining Genomic Health, Kim served as Senior Vice President, Marketing and Sales, at the biotechnology company, Genentech, Inc. During her 15 years at Genentech, Kim led the successful commercialization of 14 new therapies, including Herceptin®, the revolutionary targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer.

Kim currently serves on the boards of the California Life Sciences Association (CLSA), the Personalized Medicine Coalition (PMC), the American Clinical Laboratory Association (ACLA), and MyoKardia, Inc. Kim is also the President of The Coalition for 21st Century Medicine, and serves as an Advisor to the Healthcare Businesswomen’s Association (HBA).

Daryl Pritchard, Ph.D.  
Senior Vice President, Science Policy, Personalized Medicine Coalition

Daryl Pritchard, Ph.D., is the Senior Vice President of Science Policy at PMC, where he leads PMC’s efforts to increase awareness and understanding of personalized medicine; identify and address barriers to the adoption of personalized medicine into the health care system; and develop and promote appropriate clinical, health care infrastructure, regulatory and payment policies.

Before coming to PMC, Dr. Pritchard served as the Director of Policy Research at the National Pharmaceutical Council. Prior to joining NPC, he served as the Director of Research Programs Advocacy and Personalized Medicine at the Biotechnology Innovation Organization (BIO).

Dr. Pritchard received his Ph.D. and master’s degree in genetics from the George Washington University, and completed a post-doctoral research fellowship at the Children’s National Medical Center. Earlier, he was awarded the first American Society of Human Genetics/NHGRI Fellowship in Genetics and Public Policy.
Scott Ramsey, M.D., Ph.D.
Full Member, Fred Hutchinson Cancer Research Center; Director, Hutchinson Institute for Cancer Outcomes Research

Dr. Ramsey is a general internist and health economist. He is a Full Member in the Cancer Prevention Program, Public Health Sciences Division at the Fred Hutchinson Cancer Research Center, where he directs Hutchinson Institute for Cancer Outcomes Research, a multidisciplinary team devoted to clinical and economic evaluations of new and existing cancer prevention, screening and treatment technologies. In addition, Dr. Ramsey is a Professor in the Schools of Medicine and Pharmacy at the University of Washington.

Trained in medicine and economics, Dr. Ramsey’s research focuses on economic evaluations in cancer. He has published widely on patterns of care, costs, and cost-effectiveness of treatments for lung, colorectal, and prostate cancer. His research portfolio and interests include: large scale SEER-Medicare/Cancer Registry data linkages, patient-reported outcomes, economic modeling of health care interventions, cost-effectiveness analysis, quality of life assessment, patterns of care, health care utilization, economic burden of disease for patients and society, pragmatic trial design, early technology assessment, and stakeholder engagement.

Dr. Ramsey is Co-Chair of the Outcomes and Comparative Effectiveness Committee of the Southwest Oncology Group, past president of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and has served on the Institute of Medicine’s Cancer Policy Forum.

Salveen Richter, C.F.A.
Vice President, Research Division, Goldman Sachs

Salveen Richter, C.F.A., covers the biotechnology sector in the Global Investment Research Division at Goldman Sachs. Prior to joining Goldman Sachs in October of 2015, Salveen was a Managing Director at SunTrust Robinson Humphrey, covering biotechnology. She started her career at Jefferies, where she also covered biotechnology. Salveen received a B.S. in biomedical engineering and a minor in entrepreneurship and management from Johns Hopkins University.
William A. Sahlman, Ph.D.
Baker Foundation Professor, Harvard Business School

William Sahlman is a Baker Foundation Professor of Business Administration at Harvard Business School. Mr. Sahlman received an A.B. degree in economics from Princeton University (1972), an M.B.A. from Harvard University (1975), and a Ph.D. in business economics (1982), also from Harvard. He joined the Harvard Business School faculty in 1980.

His research focuses on the investment and financing decisions made in entrepreneurial ventures at all stages in their development. Mr. Sahlman has written numerous articles and two textbooks on topics including entrepreneurial management, venture capital, private equity, deal structuring, incentives, commercializing science, impact investing, and the role of entrepreneurship in the global economy.

In 1985, Mr. Sahlman introduced a new second-year elective course called Entrepreneurial Finance. Over 8,000 students have taken that course since it was first offered. In 2000, Mr. Sahlman helped design and introduce The Entrepreneurial Manager, a required course in the first year M.B.A. curriculum. Mr. Sahlman has published over 200 cases and notes for classroom use.

Michael Sherman, M.D., M.B.A., M.S.
Chief Medical Officer, Senior Vice President, Harvard Pilgrim Health Care; Board member, Personalized Medicine Coalition

Michael Sherman serves as Chief Medical Officer and Senior Vice President for health services for Harvard Pilgrim Health Care. A pioneer in developing outcomes-based payment agreements with pharmaceutical companies, he recently signed the first value-based agreement for a gene therapy used to treat a form of blindness.

Dr. Sherman serves as Chair of the Board of Managers of the Harvard Pilgrim Health Care Institute, and on the Advisory Board of the Institute for Clinical and Economic Review (ICER). He also is the Chair for AHIP’s CMO Leadership Council, and serves on the Board of Directors for the Personalized Medicine Coalition, and on the Board of Advisors for the Harvard Business School Healthcare Initiative.

Prior to joining Harvard Pilgrim, Dr. Sherman served as Corporate Medical Director, Physician Strategies, for Humana, and he previously held leadership positions at UnitedHealth Group, Thomson Medstat (now IBM Truven), HealthAllies, which was purchased by UnitedHealth Group in 2003, Immusol, and DaVita.

Dr. Sherman holds a B.A. in anthropology and natural sciences and an M.S. in biomedical anthropology from the University of Pennsylvania. He received his M.D. from Yale and M.B.A. from the Harvard Business School. Dr. Sherman is a diplomate of the American Board of Anesthesiology and American Board of Medical Management. In 2009, he was named a fellow of the American College of Physician Executives, and he currently serves on the faculty of the Department of Population Medicine at Harvard Medical School.
Ellen V. Sigal, Ph.D.
Chairperson, Founder, Friends of Cancer Research

Ellen V. Sigal, Ph.D., is Chairperson and Founder of Friends of Cancer Research (Friends). Friends is an advocacy organization based in Washington, D.C., that drives collaboration among partners from every health care sector to power advances in science, policy and regulation that speed life-saving treatments to patients. During the past 20 years, Friends has been instrumental in the creation and implementation of policies ensuring patients receive the best treatments in the fastest and safest way possible.

Dr. Sigal is Chair of the Board of Directors of the Reagan-Udall Foundation, a partnership designed to modernize medical product development, accelerate innovation and enhance product safety in collaboration with the U.S. Food and Drug Administration. She also serves on the Board of the Foundation for the U.S. National Institutes of Health, where she chairs its Public Private Partnerships Committee.

Lauren Silvis, J.D.
Chief of Staff, Immediate Office of the Commissioner, FDA

Lauren Silvis serves as the Chief of Staff to U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, M.D. In this capacity, she provides advice and counsel to the Commissioner and acts as the Commissioner’s direct liaison to other agencies and organizations on key initiatives. She also works closely with the agency’s individual product centers to support their implementation of agency policy and commitments. She provides strategic direction to senior leadership to advance agency priorities.

Ms. Silvis has deep expertise in all aspects of the Federal Food, Drug and Cosmetic Act and the oversight of FDA-regulated products. She has significant experience in regulatory and compliance issues, including clinical trials, premarket review and approval, product safety and promotion, import and export, and current good manufacturing practice.

Before being appointed Chief of Staff, Ms. Silvis served as Deputy Center Director for Policy in FDA’s Center for Devices and Radiological Health. In this role, she led the development and implementation of all medical device policies, regulations, and guidance, and oversaw the Center’s communication and education functions. She regularly advised on regulatory, programmatic and legislative issues affecting medical devices and represented the Center on cross-cutting agency policy issues.
Ariel D. Stern, Ph.D.
Assistant Professor, Technology and Operations Management Unit, Harvard Business School

Ariel Dora Stern is an Assistant Professor of Business Administration and Hellman Faculty Fellow in the Technology and Operations Management Unit at Harvard Business School. She teaches the Technology and Operations Management course in the M.B.A. required curriculum.

Ariel’s research focuses on the management of innovation in health care, with a focus on the medical device and pharmaceutical industries. Her projects seek to understand the drivers of innovation among firms and the determinants of how medical technologies are adopted and used in practice. Ariel is particularly interested in the intersection of the regulation, firm strategy and economics of health care. She also researches the digital transformation of medical technology and health care delivery, investigating the policy and managerial questions raised by the growth of “digital health.” Her research has been cited by Bloomberg, The New York Times, and National Public Radio.

Mark P. Stevenson, M.B.A.
Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific

Mark Stevenson has been Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific since August 2017, with responsibility for all of Thermo Fisher’s life sciences-related businesses as well as the company’s innovation and digital strategy. He joined the company as Executive Vice President and President, Life Sciences Solutions, through the acquisition of Life Technologies in 2014.

Mark previously served as President and Chief Operating Officer of Life Technologies, and President and Chief Operating Officer of Applied Biosystems prior to its merger with Invitrogen Corporation in 2008.

Mark received his M.B.A. from Henley Management School in the U.K. and his bachelor’s degree in chemistry from the University of Reading, also in the U.K.
Keith Stewart, M.B., CH.B., M.B.A.
Carlson and Nelson Endowed Director, Center for Individualized Medicine, Mayo Clinic

Keith Stewart, M.B., CH.B., M.B.A., is a consultant in the Division of Hematology and Oncology, Department of Internal Medicine, at Mayo Clinic. He currently serves as the Carlson and Nelson Endowed Director of the Mayo Clinic Center for Individualized Medicine and is recognized as the Vasek and Anna Maria Polak Professor of Cancer Research. Dr. Stewart’s current responsibilities at Mayo Clinic relate to the application of genomics to human health across the spectrum of discovery, translation and clinical practice. Dr. Stewart has served in several leadership roles across both research and clinical practice at Mayo Clinic, including as Dean for Research in Arizona, and as a member of the Arizona Executive Operations Team and Clinical Practice Committees. He has served on multiple boards for both nonprofit and commercial organizations, including currently as a Non-Executive Board member with Genomics England, OncoSpire, Inc., and OneOme, Inc.

His own research interest is in the genomics and biology of myeloma, and he has led numerous clinical trials of new drugs for this blood cancer. Dr. Stewart has over 25 years of sustained national funding for a laboratory research program and has authored over 300 journal articles and other written publications. He has served as an Associate Editor of Blood and ASH Clinical News.

Gregg Talbert, Ph.D.
Global Head of Digital and Personalized Health Care Partnering, Roche

Gregg Talbert, Ph.D., is the Global Head of Digital and Personalized Health Care Partnering at Roche. In this role, he is responsible for developing and implementing a business development strategy that supports the execution of Roche’s personalized health care strategy. Prior to serving in this capacity, Dr. Talbert served as Roche’s Global Head of Strategic Partnering. He has also served in a variety of strategy and business development positions at Eli Lilly and Company.
Edward Tepporn  
Executive Vice President, Asian and Pacific Islander American Health Forum

Ed is the Executive Vice President at the Asian and Pacific Islander American Health Forum (APIAHF). In this role, he shepherds the organization’s strategic thinking, long-term strategy planning, evaluation, innovation and leadership development efforts. With nearly two decades of service as a nonprofit manager leader and as a certified professional coach, Ed seeks to help individuals and organizations lean into their internal purpose, values and vision.

Before joining APIAHF in 2002, Ed was involved in HIV prevention and capacity building. As a former food blogger, he continues to seek out new ways to continue to pursue his passions for cooking meals that feed one’s stomach and soul as well as capturing images that spark wanderlust through digital photography.

Meg Tirrell, M.S.J.  
Reporter, CNBC

Meg Tirrell joined CNBC in April 2014 as a General Assignment Reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC’s Business Day programming, contributes to CNBC.com and is based at the network’s global headquarters in Englewood Cliffs, N.J.

Tirrell has covered development of new drugs for Alzheimer’s, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind “compassionate use” of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on the development of new medicines.

Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek. She holds a master’s degree in journalism from Northwestern University and a bachelor’s degree in English and music from Wellesley College.
Sean Tunis, M.D., M.Sc.
Founder, CEO, Center for Medical Technology Policy; Board member, Personalized Medicine Coalition

As the President and CEO of the Center for Medical Technology Policy (CMTP), Sean Tunis, M.D., M.Sc., engages multiple experts, stakeholders, and decision-makers in working toward consensus on methods for comparative effectiveness research (CER), with the goal of providing guidance for product developers and researchers as they design CER and pragmatic clinical studies. He has nearly 20 years of professional experience with health technology assessment, comparative effectiveness, health services research and clinical research.

Prior to founding CMTP, Tunis served as the Director of the Office of Clinical Standards and Quality and the Chief Medical Officer at the U.S. Centers for Medicare and Medicaid Services, where he led the development and implementation of the concept of coverage with evidence development, which was applied to support the design and implementation of several large pragmatic clinical trials and registries. For each study, he established multi-stakeholder working groups to set study objectives and decide on elements of study protocol, data collection strategy, and other aspects of these studies.

Liisa-Maria Voipio-Pulkki, M.D., Ph.D.
Director General, Chief Medical Officer, Ministry of Social Affairs and Health, Finland

Dr. Liisa-Maria Voipio-Pulkki is currently serving as the Director General of Strategic Affairs and Chief Medical Officer of the Finnish Ministry of Social Affairs and Health. She joined the Ministry in 2010 as the Director of the Health Care Group. Previously, she was employed as the Senior Medical Adviser of the Finnish Association of Local and Regional Authorities in 2004–2009, Chief of Emergency and Acute Care of the Helsinki University Hospital District in 2000–2004 and as a specialist and adjunct professor of medicine at the University of Turku, Finland.

She earned her M.D. degree in 1973 (University of Helsinki) and her Ph.D. in 1986 (University of Turku). She is a specialist in internal medicine and cardiology and has published over 100 original papers in cardiovascular medicine. Her current interests include medical and health technology innovation policies, implementation of precision medicine, sustainability of health systems, and medical ethics.

In 2017, she was elected to chair the Steering Committee of the European Observatory on Health Systems and Policies, a WHO hosted partnership, based in Brussels. She resides in Helsinki and is actively involved in the preparations for the Finnish E.U. Presidency in 2019.
Darrell M. West, Ph.D.
Vice President of Governance Studies, Director of the Center for Technology Innovation, Douglas Dillon Chair in Governance Studies, The Brookings Institution

Darrell M. West is the Vice President of Governance Studies and Director of the Center for Technology Innovation at The Brookings Institution. He holds the Douglas Dillon Chair in Governance Studies.

Previously, he was the John Hazen White Professor of Political Science and Public Policy and Director of the Taubman Center for Public Policy at Brown University. His current research focuses on technology policy, artificial intelligence and data analytics.

West is the author of 23 books, including The Future of Work: Robots, AI, and Automation (Brookings, 2018). His books have been translated into Chinese, Japanese, and Korean, and he has delivered nearly 150 lectures in a dozen different countries, including China, Japan, Russia, Taiwan, Mexico, Brazil, Germany, Netherlands, Portugal, Turkey, Bahrain, and the United States. He has been quoted in leading newspapers, on radio stations, and on national television networks around the world.

He is the winner of the American Political Science Association’s Don K. Price award for best book on technology (for Digital Government) and the American Political Science Association’s Doris Graber award for best book on political communications (for Cross Talk).
Congratulations to the Recipients of the 2018 PMC/BIO Patient Advocacy Scholarships

Recognizing that the success of personalized medicine depends on collaboration between patients and health care providers, the Personalized Medicine Coalition (PMC) partnered with the Biotechnology Innovation Organization (BIO) to offer six scholarships for patients, representatives from patient advocacy organizations, and caregivers to attend the 14th Annual Personalized Medicine Conference at Harvard Medical School.

Each scholarship includes a complimentary conference registration and a $1,000 stipend to cover transportation and lodging.

2018 Recipients

Frances Beard, lung cancer patient
Reese Garcia, Research Advocacy Manager, Fight Colorectal Cancer
Candace Henley, CEO, The Blue Hat Foundation; colorectal cancer survivor
Laura Holmes Haddad, breast cancer survivor
Eric Sokol, Senior Vice President, Public Policy, Alzheimer’s Foundation of America
Renee Westlake, Chairperson, Political Advocacy Committee, ALK Positive Worldwide; caregiver to lung cancer patient

Sponsored By

[Image of Bio logo]
Organizing Committee

Amy Abernethy, M.D., Ph.D.
Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health

Bonnie J. Addario
Founder, Chair, Bonnie J. Addario Lung Cancer Foundation; lung cancer survivor

Steven D. Averbuch, M.D.
Vice President, Head, Precision Medicine, Bristol-Myers Squibb

Mary Bordoni
Director, Alliance Development, Biotechnology Innovation Organization

Alex J. Carlisle, Ph.D.
Chairman, CEO, National Alliance Against Disparities in Patient Health

Donna R. Cryer, J.D.
President, CEO, Global Liver Institute

William S. Dalton, Ph.D., M.D.
Founder, Executive Chairman, M2Gen

Kevin Davies, Ph.D.
Executive Editor, The CRISPR Journal

Stephen L. Eck, M.D., Ph.D.
Chief Medical Officer, Immatics US

Robert C. Green, M.D., M.P.H.
Director of the Genomes2People Research Program, Professor of Medicine (Genetics), Brigham and Women’s Hospital, Broad Institute and Harvard Medical School

Richard Hamermesh, D.B.A.
Co-Faculty Chair, Harvard Business School Kraft Precision Medicine Accelerator

Dan Leonard
President, National Pharmaceutical Council

Anne-Marie Martin, Ph.D.
Senior Vice President, Global Head of Precision Medicine, Novartis

Susan McClure
Founder, Publisher, Genome magazine

Tom Miller
Founder, Managing Partner, GreyBird Ventures LLC

Cynthia Casson Morton, Ph.D.
William Lambert Richardson Professor of Obstetrics, Gynecology and Reproductive Biology, Professor of Pathology, Harvard Medical School

Lincoln Nadauld, M.D., Ph.D.
Executive Director, Precision Medicine and Precision Genomics, Intermountain Healthcare

Sukumar Nagendran, M.D.
Senior Vice President, Chief Medical Officer, AveXis

Michael J. Pellini, M.D.
Managing Partner, Section 32

Kimberly Popovits
Chairman of the Board, CEO, President, Genomic Health

Hakan Sakul, Ph.D.
Vice President, Head of Diagnostics, Worldwide Research & Development, Pfizer

Michael Sherman, M.D.
Chief Medical Officer, Senior Vice President, Harvard Pilgrim Health Care

Ralph Snyderman, M.D.
James B. Duke Professor of Medicine, Duke University

Mark P. Stevenson
Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific

Bernadette Toner
CEO, GenomeWeb

Kristin Pothier
Global Head of Life Sciences Strategy, EY Parthenon

Alex Vadas, Ph.D.
Managing Director, Partner, LEK Consulting

Jay G. Wohlgemuth, M.D.
Chief Medical Officer, Senior Vice President, Quest Diagnostics
About Us

The Personalized Medicine Coalition (PMC), representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system.
Precision medicine will soon be standard of care. And it will continue to evolve, delivering value we can’t yet imagine. Bring actionable genomic data into the clinical workflow – with a platform that can expand and scale far into the future.

Start here. Start with 2bPrecise.

More than 950,000 Cancer Patients Worldwide Have Used Oncotype DX® Tests to Individualize Their Cancer Treatments

ACCELERATING INNOVATION IN PRECISION MEDICINE

JOIN FORCES WITH LEADERS DEDICATED TO FIGHTING DISEASE

Precision medicine holds great promise for treating genetic diseases, but bottlenecks in the system are slowing its progress. To break down these barriers, Harvard Business School Executive Education in partnership with the Kraft Precision Medicine Accelerator offers Accelerating Innovation in Precision Medicine, a program focused on developing business solutions for this emerging area. Join top leaders from business, science, medicine, and technology to explore strategies for bringing new therapies to patients faster.

HARVARD BUSINESS SCHOOL
Executive Education

Accelerating Innovation in Precision Medicine
23–25 OCT 2019
Learn more www.exed.hbs.edu/precisionmedicine
Pioneering Precision Medicines…

To One Day Eliminate Cancer as a Cause of Death

Every cancer is as unique as the person facing it, which is why it is critical to treat the right patient with the right medicine at the right time. Our scientists are focused on uncovering the myriad ways that cancer grows and evades detection, with the aim of developing targeted cancer treatments designed to treat those unique characteristics—across multiple tumor types and stages of disease.

By conducting ground-breaking research and collaborating with scientists, academic institutions and like-minded science-led companies to expand capabilities, we’re breaking barriers in how we understand and fight cancer—because one day, we aim to eliminate cancer as a cause of death.
Your Precision Medicine Partner

Offering genomic solutions to help your patients live the healthiest life possible

HEREDIGENE™
Inheritance

RXMATCH™
Mental Health

EXECUTIVE HEALTH EXAM
Wellness

ICG100™
Cancer

NGS ONE™
Intelligence & Analytics

Intermountain
Precision Genomics

www.precisioncancer.com  |  (435) 251-5780  |  genomics@imail.org
Intermountain Precision Genomics Offers Comprehensive Services to Propel Personalized Medicine

PERSONALIZED MEDICINE IS THE FUTURE.
So why try to reinvent the wheel? Intermountain Precision Genomics can propel your personalized medicine initiatives into the future.

Intermountain Precision Genomics is located in St. George, Utah, amid the beautiful red rocks of the southwest. Comprehensive facilities are capable of sequencing thousands of genomes per year. Facilities include a genomics core lab, DNA sequencing lab, translational science lab, and a high throughput genomics lab that allows physicians, collaborators, and partners access to the latest genomic technologies and the highest possible quality of data to drive personalized medicine into the future.

Intermountain Precision Genomics offers an expansive circle of products that can mobilize any personalized medicine program. Services such as ICG100™, RxMatch™, HerediGene™, and NGS One™ utilize a team approach to advance personalized medicine and help people live the healthiest lives possible one patient at a time.

ICG100™ offers hope to late stage cancer patients. Our unique process analyzes the genetic makeup of a patient’s cancer and employs a skilled team of molecular tumor specialists to review each test and determine how to most effectively treat each individual cancer case. Our team gives oncologists, located anywhere in the world, the information and support they need to prepare a customized, targeted treatment plan for each patient.

RxMatch™ speeds recovery and reduces medical costs. RxMatch™ is a comprehensive DNA panel test that matches medications to the individual patient. Pharmacogenomics (PGx), or the study of how genes affect a patient’s response to medication, enables physicians to quickly find the right medication and dose for patients. Trial and error prescribing could take months, or even years, to find the right drug and dose.

HerediGene™ allows for the prevention, detection, and early treatment of inherited cancers. This molecular DNA test works hand-in-hand with physicians and genetic counselors to assess risk factors for hereditary cancers such as breast cancer. Intermountain Precision Genomics laboratories are continually working to expand the HerediGene panel to include analysis for other cancers including ovarian and colorectal cancers.

NGS One™ Genomics Service makes genomics lab capabilities available to external initiatives. NGS One™ kits provide services such as the extraction of DNA from patient samples, sequencing of human genomes and exomes, RNA sequencing, and mass cytometry and imaging services. A highly skilled team of physicians and scientists offer a variety of interpretational data including, but not limited to, experimental design of projects, variant analysis, statistical modeling, and gene transcriptomics.

Intermountain Precision Genomics translates personalized medicine into clinical practice by providing unparalleled access to genomic technology and expertise along with superior service at an affordable cost. No need to reinvent the wheel, partner with the Intermountain Precision Genomics that are on target to advance personalized medicine now and in the future.
Your past, present, and future health are written in your proteins.

We are your translator.
TRANSFORMING THE LANGUAGE OF LIFE INTO VITAL MEDICINES

At Amgen, we believe that the answers to medicine's most pressing questions are written in the language of our DNA. As pioneers in biotechnology, we use our deep understanding of that language to create vital medicines that address the unmet needs of patients fighting serious illness – to dramatically improve their lives.

For more information about Amgen, our pioneering science and our vital medicines, visit www.amgen.com

Amgen is a proud sponsor of the 14th Annual Personalized Medicine Conference

©2018 Amgen Inc. All rights reserved.

Enabling diagnostics and therapeutics for precision medicine

Our industry-leading capabilities, application expertise, and global scale help enable science and health care innovators propel a revolution in prevention, diagnosis, and treatment.

Accelerate the pursuit at thermofisher.com/precisionmedicine

© 2018 Thermo Fisher Scientific Inc. All rights reserved. COL07738 0918
Breaking News

At your fingertips

Stay Informed with the latest personalized medicine headlines from the GenomeWeb's newsroom delivers in-depth, real-time reporting on the biggest stories in life science and molecular diagnostics.

Register Today for our FREE Daily News bulletin

www.genomeweb.com

Personalized Medicine Stories

Is your story well told?

We’re brand storytellers for life sciences and healthcare, from the bench to the bedside and from clinical trials to patient stories. We specialize in media relations, content development and paid campaigns so you can focus on saving lives.
Massachusetts: The State of Possible.

Home to the #1 Life Sciences Cluster in the World.
MassBio represents 1,100+ organizations in the life sciences industry supporting members through professional development and networking, visibility and advocacy, savings, rewards and purchasing power.

STAT+
STAT Plus is a premium subscription service, offering access to exclusive, in-depth coverage of early science and clinical trials, pharma and biotech news on Wall Street, policy developments in Washington, and disruption in health care in Silicon Valley and beyond. As an attendee of the 14th Annual Personalized Medicine Conference, use the code STAT18 for 20% off your first year of STAT Plus.

As a subscriber, you’ll enjoy:
• Invitations to exclusive events, panel discussions, and networking opportunities
• Daily subscriber-only newsletters covering the day’s biggest industry headlines
• Regular live chats, webinars, and conference calls with industry experts
• Profiles of CEOs, analysts, policymakers, and leaders who shape the industry
• A powerhouse team of reporters including Ed Silverman and Adam Feuerstein
• “Cheat Sheets” on technologies, issues, and industry buzzwords

Subscribe today by going to statnews.com/subscribe
Use code STAT18 at checkout for 20% off your subscription
SAVE THE DATE

15th Annual Personalized Medicine Conference

November 13–14, 2019